Panobinostat is a potent oral deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation. It was recently approved by the US Food and Drug Administration for use in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma who have received ≥ 2 prior regimens, including bortezomib and an immunomodulatory drug. Panobinostat was approved based on results from the phase 3 PANORAMA 1 trial in patients with relapsed or relapsed and refractory multiple myeloma, which showed that panobinostat plus bortezomib and dexamethasone significantly extended progression-free survival (median, 12.0 months) compared with placebo plus bortezomib and dexamethasone (median, 8.1 months; P < .0001). Additional ongoing trials are evaluating panobinostat in combination with other partners in the relapsed/refractory and newly diagnosed treatment settings. This review focuses on panobinostat and its mechanism of action, pharmacokinetics, and clinical data in the treatment of relapsed or relapsed and refractory multiple myeloma.
Introduction
Multiple myeloma (MM) is a hematologic malignancy that accounts for ≈ 1% of all neoplasms and 13% of hematologic malignancies (1) . It is characterized by proliferation of clonal plasma cells within the bone marrow and extramedullary sites that in most instances secrete a monoclonal protein. Typical clinical characteristics include hypercalcemia, renal insufficiency, anemia, and bone disease ("CRAB features"). Other manifestations of the disease include increased risk of infection and peripheral neuropathy (PN) (2) . It has been estimated there were 24,050 new cases of MM and 11,090 deaths due to MM in the United States in 2014 (1) .
Survival of patients with MM has significantly improved over the past decade with the introduction of the proteasome inhibitors (PIs) bortezomib and carfilzomib and immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide (3, 4) .
However, these therapies are not curative, and nearly all patients with MM eventually relapse and require further therapy. The prognosis among patients with disease refractory to IMiDs and PIs is poor; among this group, only ≈ 22% respond to subsequent therapy, and among those who do respond, the median event-free survival is < 5 months and median overall survival (OS) is 9 months (3). Thus, there is a need for new treatments, particularly those with mechanisms of action that are distinct from those of IMiDs and PIs (4).
Panobinostat has also been shown to act synergistically with the PI bortezomib. This synergy can be explained in part via the effects of panobinostat on protein degradation. MM cells have high levels of protein turnover and hence a susceptibility to PIs, which inhibit metabolism and elimination of proteins generated within the cell and through this mechanism produce a proapoptotic signal. However, there is an alternative pathway of protein metabolism wherein if the proteasome cannot eliminate these proteins quickly enough, the proteins form aggregates known as aggresomes that are transported by microtubules to an autophagosome where they are degraded by lysosomes. HDAC6 interaction with tubulin and the motor protein, dynein, is critical to the transport of these protein aggregates for degradation. Inhibition of HDAC6 leads to hyperacetylated microtubules and inefficient aggresome-mediated degradation. Bortezomib inhibits proteasome degradation of protein and induces aggresome formation; coadministration of bortezomib and panobinostat, and simultaneous inhibition of the proteasome and aggresome pathways, results in synergistic cytotoxicity (11) . In addition, in vitro and in vivo models of MM have demonstrated that panobinostat in combination with bortezomib plus dexamethasone or the IMiD lenalidomide plus dexamethasone enabled dysregulation of additional genes that were not altered by doublet therapy alone (12) .
Pharmacokinetics
Panobinostat was rapidly absorbed following a single 20-mg oral dose, with a time to maximum absorption of 2 hours. The median maximum concentration was 21.2 ng/mL, and the median area under the curve was 96 ng•h/mL (13) .
Panobinostat was extensively metabolized into at least 77 metabolites. Contributions of the liver and kidney to the elimination of panobinostat were comparable, with mean 
Clinical Development
The development of panobinostat for the treatment of MM was primarily based on 5 clinical trials from phase 1 to phase 3 that included 1099 patients in total. One study included patients with advanced hematologic malignancies, while the others included only patients with MM.
A single-arm, open-label, multicenter phase 1a/2 study was conducted to determine the maximum tolerated dose (MTD) of panobinostat administered via 2 dosing schedules: 3 times per week every week or every other week. The study included 176 adult patients with hematologic malignancies that had progressed on or after available standard treatments or for whom no standard therapy existed. In patients with MM or lymphoma, 40 mg of panobinostat 7 The safety and efficacy of panobinostat monotherapy were further investigated in a 3/4 AEs included thrombocytopenia (85%), neutropenia (64%), and asthenia (30%). Only 1 patient experienced a prolonged QT interval; 2 patients each had a myocardial infarction (14) .
For the dose-expansion phase (n = 15), a noncontinuous dosing schedule (2 weeks on, 1 week off) was chosen to reduce the risk of thrombocytopenia and the need for dose interruptions. In addition, dexamethasone was given to all patients based on preclinical (12) and emerging clinical efficacy data. The ORR in the dose-expansion phase was 73%, including 20% who achieved at least a very good partial response. Of note, responses were observed in some patients with bortezomib-refractory and bortezomib and IMiD-refractory disease.
Common grade 3/4 AEs in the dose-expansion phase were thrombocytopenia (67%), neutropenia (47%), diarrhea (20%), and fatigue (20%) (14) . These results warranted further of each cycle during TP2. During both phases, patients received dexamethasone the day of and after bortezomib administration (17).
Responses included near complete (2%), partial (33%), and minimal (18%) responses for an ORR of 35% and a clinical benefit rate (CBR) of 53% (17). Among the 14 patients with highrisk cytogenetics-defined as del(17p), t(4;14), or t(14;16)-the ORR was 43% and the CBR was 71%; among the 8 patients who had del(17p), the ORR was 38% and the CBR was 88% (18). The median progression-free survival (PFS) was 5.4 months (17), and the median OS was 17.5 months (18). These results provide proof of concept that panobinostat is able to revert bortezomib resistance in some myeloma patients. Common grade 3/4 AEs were thrombocytopenia (64%), diarrhea (20%), fatigue (20%), anemia (15%), neutropenia (15%), and pneumonia (15%). No significant cardiac abnormalities were observed. There were 4 ontreatment deaths, but none were assessed as treatment related (17). Grade 3/4 laboratory abnormalities and AEs were more common in the panobinostat arm and included thrombocytopenia (67% vs 31%), lymphopenia (53% vs 40%), diarrhea (26% vs 8%), asthenia or fatigue (24% vs 12%), and PN (18% vs 15%). There were a few instances of QTcF prolongation in both arms: 5 patients in the panobinostat arm and 2 in the placebo arm had a maximum QTcF value > 480 ms, and 3 patients in the panobinostat arm and 4 in the placebo arm had a QTcF increase > 60 ms from baseline. The rate of discontinuation due to AEs was higher in the PAN arm (36%) than in the placebo arm (20%). On-treatment deaths occurred in 8% of patients in the panobinostat arm and 5% of patients in the placebo arm (19).
Safety
The safety profile of panobinostat was consistent across the clinical trials. AEs were primarily gastrointestinal and hematologic. The gastrointestinal events (diarrhea, nausea, and vomiting) were generally grade 1/2 events that could be managed through the use of antidiarrheal The most common hematologic laboratory abnormality was thrombocytopenia, which was significantly reduced via noncontinuous dosing of panobinostat, considering platelet counts tended to recover during the off-treatment week. While trials in the PANORAMA program administered panobinostat in a 2 week on/1 week off schedule, on-going trials of panobinostat in novel combinations are currently evaluating every other week and 3 week on/1 week off treatment schedules (21-23). Despite a relatively high incidence of grade 3/4 thrombocytopenia, platelet transfusions (33%), severe hemorrhages (4%), and discontinuations due to thrombocytopenia (2%) were infrequent (19).
Electrocardiogram analyses showed a low frequency of QTcF prolongation (1% and 0.5% QTcF > 480 ms in the panobinostat and placebo arms, respectively, and 0.8% and 1.1% QTcF > 60-ms increase from baseline, respectively). Additionally, T-wave and ST-segment changes were generally asymptomatic. The risk of cardiac toxicity can be reduced by monitoring electrocardiogram scans and electrolyte levels and treatment interruption in the event of QT prolongation. Deaths due to cardiac toxicity were rare: myocardial infarction was the principal cause of death in < 1% in the panobinostat arm and 0% in the placebo arm; cardiac arrest was the principal cause of death in < 1% in each arm (19). The rate of cardiac-related deaths for the panobinostat-bortezomib-dexamethasone combination was similar to that for single-agent carfilzomib (1.5%) (24).The addition of panobinostat to bortezomib plus dexamethasone did not increase the risk or severity of PN, which is a common bortezomib-related AE. In the 
67% of patients in the placebo group, and grade 3/4 PN occurred in 18% and 15% of patients in the panobinostat and placebo groups, respectively (19).
In all studies of the panobinostat-bortezomib-dexamethasone combination summarized here, bortezomib was administered intravenously, and patients received twice weekly dosing during TP1 of both PANORAMA 1 and PANORAMA 2. Recent data have demonstrated that subcutaneous administration as well as once-weekly dosing of bortezomib improve tolerability (25, 26). Thus, the safety profile of the triple combination may be improved with subcutaneous, once-weekly administration of bortezomib.
Panobinostat in the Treatment of MM
Significant advances in the treatment of MM have been made over the past decade; however, approvals have primarily been limited to agents in 2 classes (PIs and IMiDs; Table 1 These and other trials will provide insights on optimal dosing and administration, optimal combination partners, and therapeutic settings.
Conclusions and Future Directions
Panobinostat is the first DAC inhibitor approved by the US FDA for the treatment of relapsed MM and has been submitted for approval to regulatory agencies globally. In combination with bortezomib and dexamethasone, panobinostat increases PFS and the rate of high-quality responses. While this combination led to a higher rate of AEs and AE-related discontinuations than placebo, bortezomib and dexamethasone, proactive management of common AEs including panobinostat and/or bortezomib dose interruptions or reductions, should help mitigate AEs in the clinic. Anti-diarrheal therapy should be also considered at the first signs of symptoms and thorough platelet monitoring with transfusion when clinically necessary should also be considered during treatment. Additionally, recent data suggest that subcutaneous and once weekly bortezomib dosing can improve tolerability. Current trials investigating 
